Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Body Weight-Related Parameters in Pregnancies Complicated by Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis with Maternal and Perinatal Outcome Mapping.

Journal of clinical medicine·2026

Same author

How Epstein Barr virus shapes lupus autoimmunity: mechanistic insights and therapeutic perspectives.

Frontiers in immunology·2026

Same author

From Molecules to Biomarkers: Nogo Proteins and Receptors in the Early Detection of Type 2 Diabetes Complications: A Systematic Review.

International journal of molecular sciences·2026

Same author

Cardiorenal Syndrome Type 1 in Patients with Heart Failure with Preserved Ejection Fraction.

Journal of clinical medicine·2026

Same author

Evaluation of a Simple 3D Bioengineered Model: A Step Closer to Bridging the In Vitro-In Vivo Gap in Osteosarcoma Research.

Annals of biomedical engineering·2026

Same author

Multiple machine learning models for the prediction of an early response to radioactive iodine therapy in hyperthyroidism: ablative dose concept.

Thyroid research·2026

Search research articles

Related Experiment Video

Updated: May 10, 2025

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Prognostic Value of the RISK-PCI Score in Patients with Non-ST-Segment Elevation Acute Myocardial Infarction.

Ana Stanojkovic¹, Igor Mrdovic^2,3, Ivana Tosic⁴

¹Health Center Aleksinac, 18220 Aleksinac, Serbia.

Journal of Clinical Medicine

|April 26, 2025

Summary

The RISK-PCI score effectively predicts 30-day major adverse cardiovascular events (MACE) in non-ST-segment elevation myocardial infarction (NSTEMI) patients undergoing percutaneous coronary intervention (PCI). It identifies a very high-risk group needing closer monitoring.

Keywords:

MACE RISK-PCI score acute myocardial infarction non-st-segment elevation risk stratification

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

Related Experiment Videos

Last Updated: May 10, 2025

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

Area of Science:

Cardiology
Interventional Cardiology
Clinical Risk Stratification

Background:

Non-ST-segment elevation acute myocardial infarction (NSTEMI) presents a diverse patient group with varied risks.
The RISK-PCI score, developed for STEMI, was assessed for its prognostic utility in NSTEMI patients undergoing PCI.

Purpose of the Study:

To evaluate the prognostic value of the RISK-PCI score in predicting 30-day major adverse cardiovascular events (MACE) in NSTEMI patients undergoing PCI.
To identify key predictors of MACE within this patient cohort.

Main Methods:

Retrospective observational study of 242 NSTEMI patients treated with PCI.
Calculation of the RISK-PCI score using clinical, echocardiographic, and angiographic data.
Assessment of 30-day MACE as the primary outcome.

Main Results:

The incidence of 30-day MACE was 9.9%.
Independent predictors of MACE included advanced age, elevated glucose, reduced creatinine clearance, and poor post-procedural TIMI flow.
The RISK-PCI score showed good discrimination (AUC=0.725), with a significantly higher MACE risk (29.4%) in the very high-risk group (score ≥ 7).

Conclusions:

The RISK-PCI score is effective in stratifying NSTEMI patients based on 30-day MACE risk.
A very high-risk subgroup was identified, potentially benefiting from intensified management strategies.
External validation in larger populations is recommended to confirm these findings.